(Q47252017)

English

A modification of Simon's optimal design for phase II trials when the criterion is median sample size

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

A modification of Simon's optimal design for phase II trials when the criterion is median sample size (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

phase II clinical trial

0 references

author name string

Hanfelt JJ

1

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

Slack RS

2

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

Gehan EA

3

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

language of work or name

0 references

publication date

1 December 1999

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

Contemporary Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

20

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

6

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

555-566

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

An optimal three-stage design for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A design alternative for two-stage, phase II, multicenter cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Planned versus attained design in phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal three-stage designs for phase II cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Practical Bayesian guidelines for phase IIB clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0197-2456(99)00028-8

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/10588296

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47252017&oldid=2148006845"